XTL Biopharmaceuticals Ltd. XTLB
2.20
(0.21)
(8.71%)
as of 25 Sep
- Market cap
- $9.7M
- P/E
- 0.0×
Follow XTLB
| Jun '25 | Sep '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
| ROE | 0.00% | 0.00% | (34.60%) | 0.00% |
+8 more TTM periods Free account |
| ROA | 0.00% | 0.00% | (32.03%) | 0.00% | |
| ROIC | 0.00% | 0.00% | (149.76%) | 0.00% | |
| Return on Tangible Assets | 0.00% | 0.00% | (43.06%) | 0.00% | |
| Average Days of Receivables | 0.00 | 0.00 | 0.00 | — | |
| Free Cash Flow per Share | — | — | 0.00 | — | |
| Free Cash Flow | — | — | — | — | |
| Other line items | |||||
| Cash ROIC | 0.00% | 0.00% | 0.00% | 0.00% | |
| Accounts Receivable Turnover | 0.00 | 0.00 | 0.00 | — | |
| Accounts Payable Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Average Days of Payables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax Rate | — | — | 0.00 | — | |
| Research and Development Expense of Revenue | — | — | 0.00% | — | |
| Selling, General and Administrative Expense of Revenue | — | — | 0.00% | — | |
| Interest Coverage | — | — | 0.00 | — | |
| Operating CF/Net income | — | — | 0.00 | — | |
| Depreciation/Fixed assets | 0.00 | 0.00 | — | — | |
| Revenue per Share | — | — | 0.00 | — | |
| Operating CF per Share | — | — | 0.00 | — | |
| Capex per Share | — | — | 0.00 | — | |
| Net Profit Margin | — | — | 0.00% | — |
Columns are period end dates